Stay updated with breaking news from Swiss big pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roche's Genentech launches new alliance aimed at achieving greater diversity in cancer trials fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Actemra has had a mixed run in the clinical as a potential COVID-19 treatment. (Novartis) Novartis wasn’t kidding when it said it wanted to help with the global COVID-19 fight earlier this year. The company racked up back-to-back manufacturing pacts with Pfizer-BioNTech and CureVac, and, now, it’s taking the battle to the therapeutic front. Novartis has penned an initial deal with Roche to reserve active pharmaceutical ingredient (API) capacity for the company’s rheumatoid arthritis med Actemra, which has run the gamut of COVID-19 trials over the past year some successful and others not. Novartis will hold space at its drug substance facility in Singapore, where the partners expect the technology transfer to occur in the second quarter. The initial deal covers tech transfer and process validation, while the eventual plan is for Novartis to produce the API and ship it back to Roche, a company spokesperson said via email. Exact quantities will be determined by R ....